Clinical Research Directory

Inclusion Criteria: * Age ≥ 12 years at the time of signing informed consent. * Clinical diagnosis of non-segmental vitiligo with facial involvement, and total body surface area (BSA) depigmentation ≤ 10%. * Diagnosed with progressive/active vitiligo meeting at least one of the following: Vitiligo Disease Activity (VIDA) score ≥ 3. Clinical signs including trichrome vitiligo, confetti-like depigmentation, or Koebner phenomenon. The extent of lesions under Wood's lamp is larger than that visible to the naked eye. * Agrees to have no pregnancy plans and uses effective contraception during the study and up to 4 weeks after the last dose. * Voluntarily signs the informed consent form and agrees to regular follow-up visits. Exclusion Criteria: * Diagnosis of other clinical forms of vitiligo (e.g., segmental vitiligo). * Clinically diagnosed with stable vitiligo. * Co-existing skin depigmentation disorders affecting efficacy evaluation (e.g., pityriasis alba, leprosy, post-inflammatory hypopigmentation, progressive macular hypomelanosis, nevus anemicus, chemical leukoderma, tinea versicolor). * Leukoderma lesions with more than 1/3 white hair, or lesions accompanied by white hair where the investigator assesses the probability of benefit from participating is low based on clinical experience. * Contraindications to systemic corticosteroid use. * Known hypersensitivity or allergy to the study medications or excipients. * Known end-stage renal disease (ESRD) or currently undergoing renal replacement therapy (e.g., dialysis). * Concurrent participation in other clinical studies. * Any other condition which, in the investigator's judgment, makes the patient unsuitable for the study